Petros Pharmaceuticals
PTPI
PTPI was delisted on the 21st of May, 2025.
7 hedge funds and large institutions have $42.7K invested in Petros Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 7 → 7 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0.02% less ownership
Funds ownership: 0.08% → 0.06% (-0.02%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
53% less capital invested
Capital invested by funds: $90.6K → $42.7K (-$47.8K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.1K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$57 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$20.3K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$2.56K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$228 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
BlackRock
New York
| $23K | – | – | – |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $15.2K | -$20.3K | -356 | -45% |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $3K | +$4.1K | +72 | +360% |
|
|
EL
4
EMFO LLC
Weston,
Florida
| $1.4K | – | – | – |
|
5
Morgan Stanley
New York
| $24 | – | – | – |
|
|
6
Osaic Holdings
Scottsdale,
Arizona
| $20 | -$228 | -4 | -80% |
|
|
7
Bank of America
Charlotte,
North Carolina
| $19 | +$57 | +1 | New |
|
8
Wells Fargo
San Francisco,
California
| $14 | – | – | – |
|
9
First Manhattan
New York
| $13 | – | – | – |
|
|
10
UBS Group
Zurich,
Switzerland
| – | -$2.56K | -44 | Closed |
|
PTPI Hedge Fund Activity: Q1 2023 in Review
7 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Petros Pharmaceuticals (PTPI) for Q1 2023, worth a combined $42.7K — down 53% from $90.6K a quarter earlier.
Fund positioning in PTPI was balanced in Q1 2023: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was Tower Research Capital (TRC), adding an estimated $4.1K. The largest seller was Vanguard Group, cutting an estimated $20.3K.
- 7 institutional investors held Petros Pharmaceuticals (PTPI) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $42.7K of Petros Pharmaceuticals stock for Q1 2023, down 53% quarter-over-quarter.
- 1 fund opened new Petros Pharmaceuticals positions in Q1 2023 and 1 closed out, a net change of 0 holders.
- The largest Petros Pharmaceuticals buyer in Q1 2023 was Tower Research Capital (TRC), an estimated $4.1K added.
- The largest Petros Pharmaceuticals seller in Q1 2023 was Vanguard Group, an estimated $20.3K sold.
Based on aggregated 13F filings for Q1 2023.